You may be surprised, but there are companies out there that qualify as solid stocks that you can own through good times and bad.
These growth stocks possess significant clout and are leaders in their field, making them powerhouses that can help you steadily grow your investment portfolio’s value.
Such companies may also enjoy sustainable long-term tailwinds in the form of catalysts and trends that can see their businesses do well for years or even decades to come.
Others may have attributes that make them resilient to macroeconomic downturns, such as the recent raft of tariffs announced by US President Donald Trump.
Here are three attractive growth stocks that you can comfortably own for the rest of your life.
Resmed (NYSE: RMD)
Resmed is a medical device company utilising digital health technologies and cloud-connected medical devices to enable people to live healthier, more productive lives.
The company’s devices provide care for people with sleep apnea, COPD (chronic obstructive pulmonary disease), and other chronic illnesses.
The company believes it has a large and under-penetrated market of people with unmet sleep needs.
More than one billion people suffer from sleep apnea, while 860 million suffer from insomnia and 480 million from COPD, opening up many opportunities for ResMed to provide its devices and services.
The company also reported a strong set of financial results for the first nine months of fiscal 2025 (9M FY2025) ending 31 March 2025.
Revenue rose 9.7% year on year to US$3.8 billion while operating profit (excluding restructuring charges) increased by 22.7% year on year to US$1.2 billion.
Net profit excluding one-off items climbed 28.8% year on year to US$1 billion.
The business also generated a positive free cash flow of US$1.15 billion for 9M FY2025, up 31.3% year on year.
In line with the strong results, Resmed increased its quarterly dividend from US$0.50 a year ago to US$0.53.
Resmed has a strategic capital allocation framework that prioritises innovation, with 6% to 7% of its revenue invested in R&D.
Management will also actively evaluate and pursue potential acquisitions that are aligned with the company’s long-term goals and objectives.
Just last week, Resmed announced the acquisition of VirtuOx, an independent diagnostic testing facility for sleep, respiratory, and cardiac conditions.
This purchase will support Resmed’s growth in virtual care while expanding its access to diagnosis.
Meta Platforms (NASDAQ: META)
Meta Platforms is a social media company that owns popular chat app WhatsApp, video and photo sharing site Instagram, and social media platform Facebook.
The social media behemoth dominates the industry with these brands, and its various apps generate significant advertising dollars for the company that making it tough to rival.
The company reported a sparkling set of earnings for the first quarter of 2025 (1Q 2025).
Revenue rose 16% year on year to US$42.3 billion while operating profit surged 27% year on year to US$17.6 billion.
Net profit jumped 35% year on year to US$16.6 billion.
The social media company also reported a free cash flow of US$11.1 billion, down 13.7% year on year.
Capital expenditure for 1Q 2025 was elevated because of CEO Mark Zuckerberg’s commitment to spend up to US$65 billion to power its artificial intelligence (AI) goals.
Meta Platforms continued to see its family daily active people (DAP) metric improve, rising by 6% year on year to 3.43 billion, showcasing increased engagement on its platform.
The social media giant also increased its quarterly dividend from US$0.50 to US$0.525 for a 5% year-on-year increase.
Looking ahead, Meta should do well as it integrates AI into its platform to power its apps and bring in more users and advertisers.
Netflix (NASDAQ: NFLX)
Netflix is the leading streaming television (TV) player offering a broad slate of movies and TV shows on its platform.
Netflix is one of the most popular video-on-demand platforms in the US, with a market share of around 21%, losing out just slightly to Amazon Prime.
The company reported a robust set of financial results for 1Q 2025.
Revenue increased 12.5% year on year to US$10.5 billion.
Operating profit climbed 27.1% year on year to US$3.3 billion while net profit soared 23.9% year on year to US$2.9 billion.
Free cash flow for the quarter amounted to US$2.7 billion, up 24.5% year on year from US$2.1 billion.
Management forecasts 2025 revenue of US$43.5 billion to US$44.5 billion, which incorporates healthy subscriber growth, better pricing, and a near-doubling of the company’s advertising revenue.
As a comparison, 2024’s total revenue stood at US$39 billion, so this forecast will represent a year-on-year increase of between 11.5% to 14.1%.
Netflix continues to broaden its slate of shows and movies and is also testing new formats, such as a toddler learning series, Ms. Rachel.
Instead of just spending billions of dollars on producing content in the US, Netflix is now spending more on making programming abroad.
Rather than just licensing local content, the company is making local shows and films in many countries to cater to its expanding audience.
Don’t let uncertainty steal your investment momentum! While others wait for clarity, smart investors are adapting and finding new opportunities. Our webinar, “How to Invest US$20,000 Amid the Great Uncertainty,” will reveal how to cut through the noise and identify potential for growth, even amidst the Great Uncertainty. Learn to pivot your strategy and position your portfolio for the future. Click here to sign up now!
Big Tech is spending hundreds of billions on AI, and the ripple effects are just beginning. Our new investor guide shows how AI is changing the way companies generate revenue, structure their business models, and gain an edge. Even if you already know the major players, this report reveals something far MORE important: The why and how behind their moves, and what it means for your portfolio. Download your free report now.
Follow us on Facebook and Telegram for the latest investing news and analyses!
Disclosure: Royston Yang owns shares of Meta Platforms.
